Self-copying RNA vaccine wins first full approval: what’s next?

Elie Dolgin • December 6, 2023

Researchers look ahead to the potential uses and benefits of a technology that has been more than 20 years in the making.

The approval of yet another RNA-based vaccine for COVID-19 might not seem momentous. But the endorsement last week by Japanese authorities of a jab against SARS-CoV-2 constructed using a form of RNA that can make copies of itself inside cells — the first ‘self-amplifying’ RNA (saRNA) granted full regulatory approval anywhere in the world — marks a pivotal advance.


The new vaccine platform could provide potent defence against various infectious diseases and cancers. And because it could be used at a lower dose, it might have fewer side effects than other messenger RNA (mRNA) treatments have.


Continue reading at Nature.

Tubes of blood, one looks like an hourglass but with a woman's head
By Elie Dolgin April 16, 2025
Circulating biomarkers are quickly becoming a crucial part of diagnosis and disease monitoring for physicians, researchers — and even some consumers.
Zebra wearing video camera-equipped collar
By Elie Dolgin February 13, 2025
Zebras and giraffes offer one another protection without food competition.